FDA Tells a Federal Court Its Mifepristone Safety Review Will Be Complete by March 2027 — Teed Up for Possible Rollback of Mail-Order Abortion Pills
October 8, 2026. In a late-Wednesday court filing in Louisiana federal court, the Trump administration said it "plans to complete a review of the abortion drug mifepristone by March 2027, according to a court filing, paving the way for potential changes that could limit access to the pills" (Reuters). The FDA said it expects to receive the results of its safety study in December 2026 and will issue a report after interpreting them.
What the review is
Per the FDA's own filing, as reported by Reuters:
"The FDA in Wednesday's filing said its safety review involves comparing a sample of 100,000 women who used mifepristone with a comparator group who received surgical abortions. The agency said it is running a statistical analysis to detect safety risks that have not yet been identified1."
The FDA also said it is weighing petitions urging it to reinstate the in-person dispensing requirement repealed in the 2023 rule that allowed mifepristone to be prescribed remotely and dispensed by mail.
The litigation posture
The filing sits inside Louisiana's challenge to the mail-order rule — a case that has been paused pending the FDA review, along with a broader lawsuit by Texas and Florida. A third suit by Republican-led states challenging mifepristone regulations is pending in Missouri federal court. Reuters reports the review "could lay the groundwork for the FDA to repeal regulations that eased access to mifepristone... The agency could also reconsider its initial approval of mifepristone in 20002, though that would be a difficult and lengthy process."
Context
Medication abortion (mifepristone + misoprostol, within the first 10 weeks) accounted for 65% of US abortions in 2023 per the Guttmacher Institute, and use surged after Roe's 2022 overturn. Most major medical groups — and the FDA itself at various points since the 2000 approval — hold that mifepristone is safe and effective with rare serious adverse events. The December study results and the March 2027 report are now the dates to watch for any label, REMS, or access change.
-
An instance of Evidence standards now loosen for favored therapies and tighten for disfavored ones. — For a two-decade-old drug whose access the administration aims to restrict, the agency is manufacturing new evidentiary doubt — the same dial turned the other direction. ↩︎
-
An instance of Drug approvals are no longer permanent guarantees of market tenure. — A 26-year-old approval now faces a bespoke post-marketing safety study aimed at clawing back access — market tenure contested by litigation rather than guaranteed by approval. ↩︎